When Zepbound is covered, prior authorization is usually required, and the patient may need to meet clinical requirements such as a BMI of 30 or more or a BMI of 27 or more with a comorbid condition like hypertension or Type 2 diabetes, and documented weight management efforts like a low-calorie diet and increased physical activity
Start with the sponsors trial website or ClinicalTrials.gov and search for Retatrutide or LY3437943
those come from other or earlier studies and were not the standard in the headline obesity trial
Additionally, the limited supply of many of these products has increasingly shifted toward use in obesity treatment, driven by profit motives, leaving many type 2 diabetes patients unable to access medications they rely upon
Short-acting GLP-1 receptor agonists include immediate-release exenatide (Byetta) with a half-life of approximately 2.4 hours
Point estimates are represented as circles, and horizontal bars indicate 95% confidence intervals
